A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent

被引:9
作者
Catt, Susan L. [1 ]
Anderson, John L.
Chalmers, Anthony J. [2 ,3 ,4 ]
Fallowfield, Lesley J. [1 ]
机构
[1] Univ Sussex, Canc Res UK Psychosocial Oncol Grp, Brighton & Sussex Med Sch, Brighton BN1 9QG, E Sussex, England
[2] Brighton & Sussex Med Sch, Inst Postgrad Med, Brighton, E Sussex, England
[3] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[4] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
关键词
brain tumours; follow-up; high-grade glioma; service delivery; supportive care; BREAST-CANCER; LUNG-CANCER; GLIOBLASTOMA; RADIOTHERAPY; MANAGEMENT; TEMOZOLOMIDE; MODEL;
D O I
10.1111/j.1365-2753.2009.01292.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rationale and objective High-grade glioma profoundly affects patients and their families. The best ongoing care for patients completing radical treatment is uncertain. To address this issue a UK-wide audit surveying the follow-up practices of multidisciplinary cancer teams was conducted. Method An online survey package was used with a paper version available. Results Of 102 clinicians approached 86 replied, a response rate of 84%. Three-monthly outpatient department appointments led by an oncologist and a specialist nurse were the norm, but more controversially, some centres conduct joint clinics with the whole neurosurgical/oncology team present or available. Nurse-led telephone follow-up in place of hospital visits is uncommon. Regular scanning is conducted despite the clinical benefits being contentious. Access to a range of allied services providing supportive care is considered, but the actual levels of need and the efficiency with which they are delivered require further investigation. Conclusions The picture of UK follow-up practices revealed by this survey demonstrates that research is now needed to determine what preferences patients and families have for follow-up and their satisfaction with these.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 2004, IMPR SUPP PALL CAR A
[2]   Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas [J].
Brandsma, Dieto ;
Stalpers, Lukas ;
Taal, Walter ;
Sminia, Peter ;
van den Bent, Martinj .
LANCET ONCOLOGY, 2008, 9 (05) :453-461
[3]   Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [J].
Cairncross, Gregory ;
Berkey, Brian ;
Shaw, Edward ;
Jenkins, Robert ;
Scheithauer, Bernd ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperierre, Normand ;
Mehta, Minesh ;
Curran, Walter .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2707-2714
[4]   Psychosocial and supportive-care needs in high-grade glioma [J].
Catt, Susan ;
Chalmers, Anthony ;
Fallowfield, Lesley .
LANCET ONCOLOGY, 2008, 9 (09) :884-891
[5]   A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999 [J].
Chakrabarti, I ;
Cockburn, M ;
Cozen, W ;
Wang, YP ;
Preston-Martin, S .
CANCER, 2005, 104 (12) :2798-2806
[6]   Preferences for follow-up after treatment for lung cancer - Assessing the nurse-led option [J].
Cox, Karen ;
Wilson, Eleanor ;
Heath, Lesley ;
Collier, Jacqueline ;
Jones, Linda ;
Johnston, Ian .
CANCER NURSING, 2006, 29 (03) :176-187
[7]  
CURREN JR, 2007, INT J PALLIATIVE NUR, V7, P331
[8]  
Davies E, 1997, BRIT J NEUROSURG, V11, P318
[9]   Neuro-oncology practice in the UK [J].
Gerrard, GE ;
Prestwich, RJ ;
Franks, KN ;
Levy, D .
CLINICAL ONCOLOGY, 2003, 15 (08) :478-484
[10]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003